Allarity Therapeutics Q1 net loss per share narrows

Allarity Therapeutics

15/05/2026 21:39

Overview

Cancer drug developer's Q1 net loss per share narrowed from prior year

Company reduced outstanding share count through repurchase program

Cash and restricted cash rose to $29.8 mln at March 31, 2026

Outlook

Company expects stenoparib API manufacturing campaign to complete in Q3 2026 with no extra cash outlays

Allarity continues enrolling patients in Phase 2 ovarian and small cell lung cancer trials

Company expects new patent to extend stenoparib exclusivity by at least 11 years if issued

Result Drivers

COST CONTROL - Operating expenses declined slightly from prior year, reflecting financial discipline

Company press release: ID:nGNX9C3LHX

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$2.75 mln
Q1 Operating Expenses
$2.71 mln
Q1 Operating Income
-$2.69 mln


Analyst Coverage

The one available analyst rating on the shares is "buy"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Allarity Therapeutics Inc is $9.75, about 545.7% above its May 14 closing price of $1.51

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)